Our data demonstrated that the genetic ablation of UCP2 significantly increased infarct volume, brain edema, apoptosis and aggravated neurological deficit scores after ischemia/reperfusion under normoglycemic condition, which is consistent with our previous report and those published in the literature 6, 31, 32. The gene discussed is UCP2; the disease is ischemia.